Hyperlipidaemia is a major risk factor for athero sclerotic cardiovascular disease (ASCVD). Patients with familial hyper cholesterolaemia (FH) usually develop ASCVD at an early age and accumulate macrophages with intracellular lipid droplets (foam cells) in arteries, and also tendons, from childhood. The traditional paradigm for atherogenesis has focused on macrophage uptake of modified LDL and foam cell formation in arterial walls. Moreover, interactions between chemokines such as CC motif chemokine 2 (CCL2, also known as MCP1) and chemokine receptors such as CC chemokine receptor type 2 (CCR2; the receptor for CCL2) expressed on mono cytes have important roles in athero genesis mainly by mediating monocyte infiltration from the circulation into arterial walls 1 , where monocytes differentiate into macrophages, which take up modified LDL and then become lipidladen foam cells.
In an article published in European Heart Journal, Bernelot Moens et al. report that, com pared with healthy control individuals, patients with FH have higher CCR2 levels on circulating monocytes 2 . In these patients with FH, mono cyte CCR2 levels were significantly correlated with plasma LDLcholesterol levels and were positively associated with monocyte intra cellular lipid accumulation. Importantly, these changes in monocyte phenotype corre lated with enhanced monocyte migratory capacity ex vivo. Intriguingly, treatment with PCSK9 monoclonal antibodies (mAbs) in the patients in these patients 2 . In another publication, the same research group reported that mono cytes from patients with familial dysbeta lipoproteinaemia (FD) also had increased intra cellular lipid accumulation and higher expression of surface β 2 integrins, including integrinα M (CD11b), integrinα X (CD11c), and integrinβ 2 (CD18) 5 . These observations support an important role of intracellular lipid accumulation in monocyte phenotypic changes in patients with FH or FD, and are consistent with previous reports from our laboratory and others showing emergence of mono cytes with intracellular lipid droplets, which we termed 'foamy monocytes' , and monocyte phenotypic changes including increased levels of integrinα X in the circulation of humans and animals with hyperlipidaemia [6] [7] [8] [9] . Foamy monocytes emerge early in the circulation of mice with hypercholesterolaemia 6 . In humans, even a single highfat meal can increase lipid accumulation in circulating monocytes 8, 9 . Importantly, foamy monocytes infiltrate into arterial walls and contribute to the develop ment of atherosclerosis in mice with hyper cholesterolaemia 6 . The observations made by Bernelot Moens et al. of circulating monocytes with intracellular lipid accumulation ('foamy monocytes'), increased monocyte expression of chemokine receptors and adhesion molecules, and enhanced monocyte migration in patients with FH 2 or FD 5 also support an important role of these foamy monocytes in the develop ment of ASCVD in humans with hyperlipid aemia -severe hyperlipidaemia in particular. Furthermore, the findings of this study suggest that monocyte lipid accumulation in patients with FH did not rely on the LDL receptor and could be reversed by PCSK9inhibitor treat ment 2 . Indeed, our previous report showed that foamy monocytes emerge in the circu lation of mice deficient in the LDL receptor 6 , and that scavenger receptors such as platelet glycoprotein 4 (CD36), which was upregu lated in monocytes from patients with FH 2 and in mice with hyperlipidaemia 6 , might have important roles in monocyte uptake of cholesteryl esterrich lipoproteins and foamy monocyte formation in the circulation 6 . Monocytes are heterogeneous cell popula tions and are commonly classified in humans into three subsets (classical, intermediate, and nonclassical). Most previous studies indicated that levels of intermediate and/or with FH lowered plasma LDLcholesterol levels by ~50% and reduced intracellular lipid accu mulation and CCR2 levels in circulating mono cytes, with reversal of the enhanced migratory capacity of monocytes. Given the role of mono cytes, chemokines, and chemokine receptors in the development of athero sclerosis 1 , these findings are important in helping us to under stand further the mechanisms for the early development of ASCVD in patients with FH.
PCSK9 mAb inhibitors are a new class of drugs that lower plasma LDLcholesterol levels. Large clinical trials have shown that PCSK9 inhibitors combined with background maximally tolerated statin therapy reduce the risk of cardiovascular events, particularly in patients who continue to have elevated LDLcholesterol levels at baseline 3, 4 . Although PCSK9 inhibitors do not reduce levels of Creactive protein, the shift to a less athero genic monocyte phenotype with PCSK9 mAb treatment reported by Bernelot Moens et al. provides evidence in humans that these thera pies might alter the 'inflammatory response' in a beneficial way, consistent with evidence for the beneficial roles of this class of drugs in the treatment of ASCVD 3, 4 . Also important were the observations made by Bernelot Moens et al. that the number of circulating monocytes with intracellular lipid accumulation and monocyte migratory cap acity was increased in patients with FH, and that intracellular lipid content was positively associated with monocyte levels of CCR2 nonclassical monocytes were increased in hyperlipidaemia and associated with ASCVD. Bernelot Moens et al. reported that the above phenotypic changes occurred mainly in classi cal monocytes, and that the ratios of each monocyte subset did not change in patients with FH or FD compared with healthy con trols 2, 5 . By contrast, Christensen et al. showed that, compared with healthy controls, children with FH, particularly those with low HDL cholesterol levels, had higher circulating intermediate and nonclassical monocytes and lower levels of classical monocytes 10 . From the articles by Bernelot Moens et al., we note that the researchers followed the common gating strategy for flow cytometric analyses of mono cytes (with low side scatter pattern) in patients with FH or FD 2, 5 . However, from our previous studies, mainly in mouse models of hyper cholesterolaemia, we realized that the flow cytometry gating strategy had to be revised in order to examine foamy monocytes, particu larly monocytes with abundant lipid drop lets, which displayed dramatic elevations in granularity with high side scatter pattern and, therefore, appeared in granulocyte regions 6, 7 . Moreover, foamy monocytes had different phenotypes from nonfoamy monocytes in the same animals 6, 7 . Therefore, it would be ideal to examine whether foamy monocytes that shifted their patterns to granulocyte regions were also present in the samples from these patients with FH or FD, and if so, to identify what the phenotypes and functions of these monocytes with elevated side scatter pattern are in these patients.
In summary, in addition to the current para digm for atherogenesis with a focus on macro phage uptake of modified LDL and foam cell formation in arterial walls, reports 2, [5] [6] [7] [8] [9] from Bernelot Moens et al., our group, and others support a novel model of athero genesis, in which hyperlipidaemia -severe hyperlipidaemia in particular -causes cir culating monocytes to take up lipoprotein particles, lead ing to increased intracellular lipid accumula tion and foamy monocyte for mation in the circulation. Intracellular lipid accumulation in circulating monocytes might induce monocyte phenotypic changes that enhance monocyte migration from the circu lation into arterial walls, accelerate monocyte differenti ation into foamy macrophages in arterial walls, and, therefore, contribute to the development of atherosclerosis. Treatment with lipidlowering drugs such as PCSK9 inhibitors reduces monocyte levels of intracellular lipids and improves monocyte phenotypes with decreased monocyte migration and might thereby prevent progression and enhance regression of athero sclerosis (FIG. 1) . Further studies are needed to determine, particularly in patients with hyperlipidaemia, whether foamy monocytes have unique phenotypes compared with monocytes with little or no lipid accumu lation from the same individual, whether foamy monocytes can help to identify individ uals at high risk of cardiovascular disease who might benefit from lipidlowering therapy, and whether therapies that target foamy mono cytes and 'improve' monocyte phenotypes are associated with clinical ASCVD benefits. 
